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Accelerated and hyperfractionated
schedules
Analysis of the sets of data of accelerated,
predominantly accelerated and
hyperfractionated radiation treatments shows
that, except with hyperfractionation and short
single course accelerated regimens, the AD is
not constant in consecutive weeks of treatment.
High AD, above 25 Gy is typical for accelerated
treatments when the dose is condensed into a
single course in a short overall treatment time.
Conclusions
1. When fractionation regimens are altered to
achieve a therapeutic gain through an increased
tumour response relative to late normal tissue
response, acute mucosal reactions become
dose limiting in radiotherapy for head and
cancer.
2. Acceptable risk of acute mucositis can be
expected when the Dose-Time Ratio (DTR) is
lower than 2.5 Gy x day -2 and accumulated
dose per week (AD) is less than 12 Gy. Higher
AC can only be considered if it is administered
in no more than 2 consecutive weeks of 5-6
week treatment or 2-3 week split is given
between series of high AD (or DTR).
3. High constant value of the AD (>14 Gy)
during 5-6 weeks of treatment or the AD above
20 Gy and DTR above 10 Gy x day-2 lead to
high risk of persistent confluent mucositis and
consequential late necrosis which may occur
within 4-8 months after treatment.
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We have designed phase 1111 human
melanoma gene therapy clinical protocol. The
aim of the study was to actively immunize HLA-
A1 and/or HLA-A2-positive patients with
melanoma with an admixture of irradiated
autologous tumor cells and allogeneic
melanoma cells genetically engineered to
secrete IL-6 and sIL-6R in order to elicit or
enhance specific and nonspecific anti-
melanoma immune responses to autologous
tumor cells to eradicate distant melanoma
lesions. Irradiation of autologous and allogeneic
tumor cells is a key step in preparation of
cellular vaccine because of two major reasons,
(i) it inhibits cell proliferation which is crucial in
the case of autologous cells which may form a
tumor; (ii) it increases melanoma vaccine
immunogenicity. The aim of the study was to
estimate the optimal dose of ionizing radiation
which will provide sterilization of both
autologous and allogeneic melanoma cells and
will ensure cytokine secretion.
Human melanoma cells (Mich-1) were
transduced with IL-6 and sIL-6R cDNA using
double copy bicistronic retroviral vector. Parental
and transduced cells were seeded at in six-well
tissue culture plates and were irradiated with 10,
47
50, 100 and 200 Gy. Secretion of both
recombinant proteins into culture was analyzed
before and 24, 48,72, 96 hand 6, 7, 10 and 12
days following irradiation. At the same time
adherent cells were enumerated, evaluated for
viability and proliferation. At 24, 48, 72 and 96 h
postirradiation specific IL-6 and sIL-6R mRNA
levels were analyzed.
Irradiation of gene modified cells
inhibited their proliferation in the dose
dependant manner. Dose of 50 Gy sufficiently
affected cell proliferation, however, for safety
reasons we decided to use the dose of 100 Gy
for vaccine preparation. Irradiation did not inhibit
secretion of IL-6 and sIL-6R. In contrary, on a
per cell basis it significantly increased their
secretion which lasted 12 days postirradiation.
Interestingly, we did not observe dose or time
dependent differences in specific mRNA cellular
levels suggesting that increased secretion of
both proteins is regulated not on the
transcriptional but rather on the
posttranscriptional level. Taking all these facts
into account we concluded that irradiation of
tumor cells may provide an effective and safe
approach for gene-modified vaccine
preparation.
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